Immix Biopharma, Inc. (IMMX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Immix Biopharma, Inc. (IMMX) closed at USD 8.51 on 2026-10-14, a change of +118.2 % over the past year, with a market capitalization of USD 719.6M.

Immix Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Immix Biopharma, Inc. key figures

Previous close

USD 8.51 (2026-10-14)

1-year change

+118.2 %

Market cap

USD 719.6M

Enterprise value

USD 389.86M

P/E ratio (trailing)

-9.86

P/E ratio (forward)

-10.24

EPS (trailing)

-0.88

EPS (forward)

-0.85

PEG ratio

n/a

Price to book

2.71

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

6.23

Employees

21

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Immix Biopharma, Inc.

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Immix Biopharma, Inc. and compare it with other stocks.